



Glaucius Oliva – 60 anos


Cris/Cristininha/Cristy Nonato


➤ **“FAMILIES ARE LIKE BRANCHES ON A TREE. WE GROW IN DIFFERENT DIRECTIONS YET OUR ROOTS REMAIN AS ONE”**



TIMELINE

- (1997 – 1999) POS/ DOC @ IFSC/ USP – GLAUCIUS OLIVA
- (1999 – 2002) POS/ DOC @ CORNELL UNIVERSITY – JON CLARKE
- (2002 – 2006) YOUNG RESEARCHER – FAPESP @ FCFRP – USP
- (2005) PEDRO WAS BORN
- (2006 – 2012) ASSISTANT PROFESSOR @ FCFRP – USP
- (2007) RAFAELA WAS BORN
- (2012 – NOWADAYS) ASSOCIATE PROFESSOR @ FCFRP – USP
- (2017 – 2018) SABATICAL AT THE BROAD INSTITUTE AT MIT AND HARVARD – STUART SCHREIBER
- (2018 – NOWADAYS) VICE/ COORDINATOR OF PPGCF/ FCFRP/ USP
- (2018 – NOWADAYS) VICE/ PRESIDENT OF THE BRAZILIAN CRYSTALLOGRAPHIC ASSOCIATION





**LABORATÓRIO DE CRISTALOGRAFIA DE PROTEÍNAS
FACULDADE DE CIÊNCIAS FARMACÊUTICAS DE RIBEIRÃO
PRETO
UNIVERSIDADE DE SÃO PAULO**

- **STRUCTURAL BIOLOGY APPLIED TO MEDICINAL CHEMISTRY**

SUPERVISIONS AND GRANTS

CONCLUDED

- 20 Undergrads
- 8 Master students
- 7 PhD students
- 6 pos/ docs

CURRENTLY

- 4 undergrads
- 2 master students
- 1 PhD student
- 1 pos/ doc

CONCLUDED

- 9 research projects
- 24 Scholarships
- 5 Scholarships abroad

CURRENTLY

- 2 Research projects – Regular FAPESP/ Universal (CNPq)
- undergrads
- 5 Scholarships



MAIN PROJECTS

- ▶ DIHYDROOROTATE DEHYDROGENASE: Human, *Plasmodium falciparum*, *Schistosoma mansoni*, *Trypanosoma cruzi*, *Leishmania major*, *Leishmania braziliensis*, *Pseudomonas aeruginosa*;
- ▶ FUMARATE HYDRATASE: Human, *Schistosoma mansoni*, *Trypanosoma cruzi*, *Leishmania major*;
- ▶ NITROREDUCTASES: *Trypanosoma cruzi*, *Leishmania major*, *Trypanosoma brucei*;
- ▶ HUMAN GALECTINS: *Galectin 4*, *galectin 12* and *galectin 1*;
- ▶ HUMAN PRION PROTEIN

SmDHODH – ATOVAQUONE REPORPUSING



Biochimie 158 (2019) 180–190



Contents lists available at ScienceDirect

Biochimie

journal homepage: www.elsevier.com/locate/biochi



Research paper

Structural basis for the design of selective inhibitors for *Schistosoma mansoni* dihydroorotate dehydrogenase

M. Cristina Nonato ^{a,*}, Ricardo A.P. de Pádua ^a, Juliana S. David ^a, Renata A.G. Reis ^a,
Giovani P. Tomaleri ^a, Humberto D'Muniz Pereira ^b, Felipe A. Calil ^a

^a Laboratório de Cristalografia de Proteínas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 14040-903, Brazil

^b Centro de Biotecnologia Molecular Estrutural, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP, 13560-970, Brazil



Atovaquone




Table 1

Inhibitory potential (IC₅₀) in nM for the compounds tested against HsDHODH and SmDHODH and their selectivity index. Error represents standard error of the fit. Single experiment in triplicate.

IC ₅₀ (nM)	Atovaquone	Brequinar	DSM265	Teriflunomide
Enzyme				
HsDHODH	2600 ± 200	37 ± 2	7000 ± 1000	320 ± 40
SmDHODH	430 ± 20	20000 ± 1000	21000 ± 1000	50000 ± 2000
Selectivity index	6 (SmDHODH)	540 (HsDHODH)	3 (HsDHODH)	156 (HsDHODH)

Table 11. *In vitro* effects of Compounds 2, 6i and 17 against 49-day-old adult *Schistosoma mansoni*.

Group	Incubation period (h)	Sex	Dead worms (%) ^a	Motor activity (%) ^a		Worms with tegumental alterations (%) ^a	
				Normal	Altered	Partial	Extensive
Control ^b	24	Male	0	100	0	0	0
		Female	0	100	0	0	0
	48	Male	0	100	0	0	0
		Female	0	100	0	0	0
	72	Male	0	100	0	0	0
		Female	0	100	0	0	0
96	Male	0	100	0	0	0	
	Female	0	100	0	0	0	
PZQ ^c	24	Male	100	0	0	0	100
		Female	100	0	0	0	100
	48	Male	100	0	0	0	100
		Female	100	0	0	0	100
	72	Male	100	0	0	0	100
		Female	100	0	0	0	100
96	Male	100	0	0	0	100	
	Female	100	0	0	0	100	
ATOVAQUONE Compound 2 50 μ M	24	Male	17	17	66	17	50
		Female	0	17	83	17	0
	48	Male	17	17	66	50	50
		Female	17	0	83	33	66
	72	Male	17	0	83	0	100
		Female	66	0	33	0	100
96	Male	66	0	33	0	100	
	Female	66	0	33	0	100	
Compound 6i 5 μ M	24	Male	0	100	0	0	0
		Female	0	83	17	0	0







Figure 16. *In vitro* effect of Compounds 2, 6i and 17 on *Schistosoma mansoni* oviposition. Adult worm couples were incubated with Compounds 2, 6i and 17, and at the indicated time periods, the cumulative number of eggs per worm couple was assessed and scored using an inverted microscope. Values are means \pm SD (bars) for six worm couples.

REPOSITIONING OF ANTIMALARIAL DRUGS FOR THE TREATMENT OF SCHISTOSOMIASIS

BASED ON SELECTIVE INHIBITION OF *SmdHODH*



MMV
Medicines for Malaria Venture



Trypanosomatidae DHODHs

Biochimie 94 (2012) 1739–1748

Contents lists available at SciVerse ScienceDirect

Biochimie

journal homepage: www.elsevier.com/locate/biochi

Research paper

Crystal structure of dihydroorotate dehydrogenase from *Leishmania major*

Artur T. Cordeiro¹, Patricia R. Feliciano, Matheus P. Pinheiro, M. Cristina Nonato*

Laboratório de Cristalografia de Proteínas, Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, Monte Alegre, Ribeirão Preto 14040-903, S.P, Brazil

Available online at www.sciencedirect.com

ScienceDirect

Biochemical and Biophysical Research Communications 369 (2008) 812–817

BBRC



www.elsevier.com/locate/ybbrc


Crystal structure of *Trypanosoma cruzi* dihydroorotate dehydrogenase from Y strain

Matheus P. Pinheiro^a, Jorge Iulek^b, M. Cristina Nonato^{a,*}

^a Laboratório de Cristalografia de Proteínas, Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto S.P. 14040-903, Brazil


^b Setor de Ciências Exatas e Naturais, Departamento de Química, Universidade Estadual de Ponta Grossa, Ponta Grossa P.R. 84030-000, Brazil






INHIBITOR SEARCH FOR TRYPDHDHS BY HTS-HIGHTHROUPUT SCREENING


Small diversity (EasySet) Potency assay




IC50 = 0.257 μ M



IC50 = 1.3 μ M




IC50 = 1.1 μ M



IC50 = 2.2 μ M

TRYPANOSOMATIDADE FUMARASES






Crystal structure of an Fe-S cluster-containing fumarate hydratase enzyme from *Leishmania major* reveals a unique protein fold

Patrícia R. Feliciano^{a,b,c}, Catherine L. Drennan^{b,c,d,1}, and M. Cristina Nonato^{a,1}

^aLaboratório de Cristalografia de Proteínas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo 14040-903, Brazil; ^bDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139; ^cDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and ^dHoward Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139

PNAS






- Treatment of arthritis
- Low toxicity in human

CUTANEOUS LEISHMANIASIS

CELL CULTURE AND IN VIVO ASSAYS

IONTOPHORESIS





Stuart Schreiber



Flavio Emery




Fernanda Anibal




UNIVERSIDADE
FEDERAL DA
BAHIA

Marcelo Castilho



Milagros Medina



David Gray



Karl Hoffmann



Nubia Boechat



Catherine Dreenan



Jared Rutter



FINANTIAL SUPPORT



CAPES

CAPE2



Em



NPq

**30 YEARS OR SO OF PROTEIN
CRYSTALLOGRAPHY IN BRAZIL: The green olive
BR800 contribution**



Estruturas complexas

Autodeclarado domador de moléculas, físico dá pesquisa científica à gestão administrativa

Maria Guimarães / Retrato: Léo Ramos Chaves

A partir de Glaucius Oliva por domar proteínas para o desenvolvimento de fármacos nasceu na graduação de um desafio de engenharia: descobrir como unir elementos de pecinhas de plástico na forma de uma molécula de mioglobina. Foram meses de trabalho para calcular a posição e a orientação exatas de cada átomo e posicioná-los, todos, firmando as partes e encaixando-as em traves cortadas no comprimento exato. A partir daí, o estudante de engenharia elétrica sabia o que queria fazer.

Se não sabia que esse interesse científico exigiria também que se dedicasse desde o início da carreira a congregação de recursos em áreas diferentes para trabalhar em conjunto e a convencer agências de fomento e instituições de pesquisa a financiá-los, Glaucius Oliva tornou-se então um destacado gestor, tanto em grandes projetos interdisciplinares como à frente do Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), que presidiu entre 2011 e 2015. Professor no Instituto de Física do campus de São Carlos da Universidade de São Paulo (USP), atualmente dirige o Centro de Pesquisa e Inovação em Biodiversidade e Fármacos (CIBFar), um dos Centros de Pesquisa, Inovação e Difusão (Cepid) financiados pela FAPESP.

Oliva concedeu esta entrevista em sua sala decorada pelo modelo molecular montado há cerca de 40 anos (com ele na foto ao lado), em um instituto praticamente vazio às vésperas do Natal. Seu laboratório estava ativo.

FORMAÇÃO
 Especialização em Física, Instituto de Física de São Carlos, Universidade de São Paulo (USP), 1983
FORMAÇÃO
 Graduação em Engenharia Elétrica, Instituto de Engenharia de São Carlos, Universidade de São Paulo (USP), 1981
FORMAÇÃO
 Mestrado em Física, Instituto de Física de São Carlos, Universidade de São Paulo (USP), 1983
FORMAÇÃO
 Doutorado em Física, Instituto de Física de São Carlos, Universidade de São Paulo (USP), 1986
PRODUÇÃO CIENTÍFICA
 163 artigos



UNIVERSIDADE DE SÃO PAULO
 INSTITUTO DE QUÍMICA DE SÃO CARLOS

FORMULÁRIO DE APROVEITAMENTO DE ESTUDOS

ATENÇÃO

Nome do aluno: _____
 Matrícula: _____
 Curso: _____

Disciplinas cursadas:

Nome	
Integral e Integral 1	
Integral 2	
Química Experimental	
Química Analítica	

Disciplinas da FCFRP para DP:

Nome	
Básicas	

de 201

Serviço de Gr